Retacrit is the sixth biosimilar to be marketed in the United States. It currently is the only biosimilar erythropoiesis-stimulating agent available.

The websites FiercePharma and The Center for Biosimilars both reported the product launch, stating that Retacrit was shipping to wholesalers at a list price of $11.03 per 1,000 units/mL. This represents a 57% discount to Procrit and a 33.5% discount to Epogen.